Literature DB >> 6447137

The pharmacokinetics of LY127935, a broad spectrum oxa-beta-lactam.

R Wise, S Baker, N Wright, R Livingston.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6447137     DOI： 10.1093/jac/6.3.319

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  10 in total

1.  Effect of pancreatitis on moxalactam excretion in pancreatic fluids of dogs and man.

Authors:  E Rubinstein; D Meissel; E Klein; Y Samra; R Schwartzkopf; G Ben-Ari
Journal:  World J Surg       Date:  1988-06       Impact factor: 3.352

2.  Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime.

Authors:  R Lüthy; J Blaser; A Bonetti; H Simmen; R Wise; W Siegenthaler
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

Review 3.  The third generation cephalosporins.

Authors:  B Farber; R C Moellering
Journal:  Bull N Y Acad Med       Date:  1982-11

4.  Studies on lamoxactam penetration into the aqueous humor of the human eye.

Authors:  K F Manthey; U Ullmann
Journal:  Infection       Date:  1983 Jul-Aug       Impact factor: 3.553

5.  Pharmacokinetics of Ro 13-9904, a broad-spectrum cephalosporin.

Authors:  M Seddon; R Wise; A P Gillett; R Livingston
Journal:  Antimicrob Agents Chemother       Date:  1980-08       Impact factor: 5.191

6.  Ceftriaxone: in vitro studies and clinical evaluation.

Authors:  J W Gnann; W E Goetter; A M Elliott; C G Cobbs
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

7.  Pharmacokinetics of ceftriaxone in humans.

Authors:  I H Patel; S Chen; M Parsonnet; M R Hackman; M A Brooks; J Konikoff; S A Kaplan
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

Review 8.  Moxalactam (latamoxef). A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; J A Romankiewicz; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-10       Impact factor: 9.546

9.  Epimers of moxalactam: in vitro comparison of activity and stability.

Authors:  R Wise; P J Wills; K A Bedford
Journal:  Antimicrob Agents Chemother       Date:  1981-07       Impact factor: 5.191

10.  Pharmacokinetics of moxalactam in subjects with normal and impaired renal function.

Authors:  A Leroy; G Humbert; J P Fillastre
Journal:  Antimicrob Agents Chemother       Date:  1981-06       Impact factor: 5.191
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.